BioMimetic Raises Additional $11.8 Million in Equity Financing

BioMimetic Pharmaceuticals, a biotherapeutics company focused on the development of products for the treatment of musculoskeletal disorders, announced a second closing of its Series C round of financing raising an additional $11.8 million. This brings the total funds raised in the Series C round to approximately $38 million. The company raised $25.7 million in an earlier closing of the Series C round. Investors in the most recent financing include Noro-Moseley, PTV Sciences, Axiom Ventures and HSS Ventures.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/05-18-2005/0003636263&EDATE=)